What is the typical dosing for Cagrilintide?

Doses from clinical trials - not yet approved. Common doses observed in research: 2.4 mg weekly (monotherapy), 2.4 mg weekly + semaglutide 2.4 mg (CagriSema). Duration: Long-term / chronic use expected. Administration: Subcutaneous injection once weekly.

Weight Loss

Cagrilintide

Also known as: AM833, NN9838, CagriSema (combination)

Clinical Trials

Buy in shop

Cagrilintide from $108/kit

3 verified vendors, ≥99% purity, COAs included.

Compare prices

Key Facts: Cagrilintide

Category: Weight Loss
FDA Status: Not FDA Approved
Clinical Status: Phase 3 Trials - Primary path via CagriSema combo (cagrilintide + semaglutide). NDA submitted Dec 2025, FDA decision expected Q4 2026.
Administration: Subcutaneous injection once weekly
Typical Dose: 2.4 mg weekly
Frequency: Once weekly
Duration: Long-term / chronic use expected

Also Known As

AM833, NN9838, CagriSema (combination)

Mechanism of Action

Cagrilintide mimics amylin, a hormone co-secreted with insulin from pancreatic beta cells. It activates amylin and calcitonin receptors in the area postrema and nucleus tractus solitarius of the brainstem, enhancing satiety signaling. Unlike GLP-1 agonists, it works through homeostatic and hedonic appetite centers, reducing hunger and promoting earlier meal termination. Also slows gastric emptying to prolong fullness.

Research Summary

REDEFINE 1 Phase 3 trial showed 11.8% weight loss with cagrilintide monotherapy vs 2.3% placebo over 68 weeks. Combined with semaglutide (CagriSema), average weight loss reached 20.4% vs 3.0% placebo. 60% of CagriSema participants achieved ≥20% weight loss, and 23% lost ≥30%. This represents some of the most significant weight loss results seen with any anti-obesity medication.

Trial Progress:Phase III

Pre

III

FDA

Dosing Information

Human Trials·Phase 3 clinical trials completed, awaiting FDA approval

Typical DosingⓘDoses commonly used by people in practice, based on community reports and anecdotal experience.

Community experience

Common Dose

2.4 mg weekly

Range

1.0-2.4 mg weekly (dose escalation)

Frequency

Once weekly

Most effective when combined with semaglutide (CagriSema). Works through amylin pathway which is complementary to GLP-1 mechanism. Dose escalation typically used to minimize GI side effects. Not yet commercially available - still in clinical trials.

Research DosingⓘDoses from published scientific studies and clinical trials. May include human or animal research.

Scientific studies

Doses from clinical trials - not yet approved

Doses from Studies

2.4 mg weekly

REDEFINE 1 Trial - Phase 3 - 11.8% weight loss as monotherapy ↗

2.4 mg cagrilintide + 2.4 mg semaglutide weekly

REDEFINE 1 Trial (CagriSema) - Phase 3 - 20.4% weight loss with combination ↗

Duration

Long-term / chronic use expected

Administration

Subcutaneous injection once weekly

Timing & Administration

Best Time to Take

Any consistent time weekly

Once weekly

Food Recommendation

With or without food

Why This Timing?

Once-weekly injection provides sustained amylin receptor activation. Timing is flexible but should be consistent week to week.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

●Nausea (common, usually transient)
●Vomiting
●Diarrhea
●Constipation
●Abdominal pain
●Injection site reactions
●Decreased appetite
●Headache
●Dyspepsia
●GI events affected 79.6% in CagriSema trials (mostly mild-moderate)
●Limited long-term safety data - still in trials

References

Research This Peptide Further

PubMed ClinicalTrials.gov FDA.gov

Buy in shop

Cagrilintide from $108/kit

3 verified vendors, ≥99% purity, COAs included.

Compare prices

Frequently Asked Questions

What does Cagrilintide do?

A long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).

How does Cagrilintide work?

Is Cagrilintide FDA approved?

No, Cagrilintide is not currently FDA approved. Current status: Phase 3 Trials - Primary path via CagriSema combo (cagrilintide + semaglutide). NDA submitted Dec 2025, FDA decision expected Q4 2026.

What are the side effects of Cagrilintide?

Reported side effects include: Nausea (common, usually transient), Vomiting, Diarrhea, Constipation, Abdominal pain. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Cagrilintide?

Community-reported common dose: 2.4 mg weekly (Once weekly). Range: 1.0-2.4 mg weekly (dose escalation). Administration: Subcutaneous injection once weekly. Investigational drug - not yet approved. Clinical trial doses shown. Not medical advice.

Related Peptides

Peptides commonly compared with Cagrilintide or used in similar applications.

Semaglutide

FDA

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

Weight Loss

Liraglutide

FDA

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.

Weight Loss

Retatrutide

Clinical Trials

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.

Weight Loss

Survodutide

Clinical Trials

A dual GLP-1/glucagon receptor agonist in development for obesity and MASH. Has FDA Breakthrough Therapy Designation for MASH with fibrosis.

Weight Loss

Eloralintide

Clinical Trials

A next-generation oral GLP-1 receptor agonist developed by Structure Therapeutics (now Ventyx Biosciences). Shows comparable weight loss to injectable GLP-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing.

Weight Loss

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.

Weight Loss

How to Use Cagrilintide Cagrilintide Alternatives Compare with Similar Browse All Peptides

Want updates on Cagrilintide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides